Vericel/$VCEL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vericel
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Ticker
$VCEL
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
357
ISIN
US92346J1088
Website
Vericel Metrics
BasicAdvanced
$2.1B
798.48
$0.05
1.34
-
Price and volume
Market cap
$2.1B
Beta
1.34
52-week high
$63.00
52-week low
$37.39
Average daily volume
482K
Financial strength
Current ratio
5.01
Quick ratio
4.203
Long term debt to equity
29.715
Total debt to equity
33.532
Interest coverage (TTM)
-4.57%
Profitability
EBITDA (TTM)
4.003
Gross margin (TTM)
72.54%
Net profit margin (TTM)
1.25%
Operating margin (TTM)
-1.18%
Effective tax rate (TTM)
4.73%
Revenue per employee (TTM)
$670,000
Management effectiveness
Return on assets (TTM)
-0.45%
Return on equity (TTM)
1.13%
Valuation
Price to earnings (TTM)
798.476
Price to revenue (TTM)
8.575
Price to book
7.06
Price to tangible book (TTM)
7.21
Price to free cash flow (TTM)
-309.549
Free cash flow yield (TTM)
-0.32%
Free cash flow per share (TTM)
-13.41%
Growth
Revenue change (TTM)
14.80%
Earnings per share change (TTM)
521.85%
3-year revenue growth (CAGR)
14.79%
10-year revenue growth (CAGR)
19.66%
3-year earnings per share growth (CAGR)
-40.05%
10-year earnings per share growth (CAGR)
-28.78%
What the Analysts think about Vericel
Analyst ratings (Buy, Hold, Sell) for Vericel stock.
Bulls say / Bears say
Vericel reported a 20% increase in total revenue for 2024, reaching $237.2 million, with MACI revenue growing by 20% and Burn Care revenue by 22%, indicating strong product demand and market expansion. (stockinvest.us)
Analysts from Truist Securities and BTIG have maintained 'Buy' ratings for Vericel, with price targets of $61 and $63 respectively, reflecting confidence in the company's growth prospects. (investing.com, reuters.com)
Vericel's strategic focus on increasing the use of MACI Arthro and dedication to mid-term financial goals have bolstered investor confidence, as highlighted by recent analyst reports. (tipranks.com)
Truist Securities reduced Vericel's stock price target from $67 to $61, citing a $2 million shortfall in Epicel revenue, which may indicate challenges in meeting revenue expectations. (investing.com)
Vericel's Q1 2025 revenue guidance was noted to be below consensus estimates, suggesting potential near-term revenue growth challenges. (investing.com)
Insider selling activity, including the CEO's sale of 26,592 shares, might raise concerns about internal confidence in the company's future performance. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jun 2025.
Vericel Financial Performance
Revenues and expenses
Vericel Earnings Performance
Company profitability
Vericel News
AllArticlesVideos
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025
GlobeNewsWire·4 weeks ago
Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance
GlobeNewsWire·2 months ago
Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vericel stock?
Vericel (VCEL) has a market cap of $2.1B as of July 10, 2025.
What is the P/E ratio for Vericel stock?
The price to earnings (P/E) ratio for Vericel (VCEL) stock is 798.48 as of July 10, 2025.
Does Vericel stock pay dividends?
No, Vericel (VCEL) stock does not pay dividends to its shareholders as of July 10, 2025.
When is the next Vericel dividend payment date?
Vericel (VCEL) stock does not pay dividends to its shareholders.
What is the beta indicator for Vericel?
Vericel (VCEL) has a beta rating of 1.34. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.